Beijing Tide Pharmaceutical Co., Ltd   Report issue

For profit Phase 2
Founded: BEIJING China (1995)
Status: No NME R&D (1995)

Organization Overview

First Clinical Trial
2014
NCT02030769
First Marketed Drug
2021
colesevelam (welchol)
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

BEIJING TIDE PHARM | Beijing Tide Pharmaceutical Co., Ltd | BEIJING TIDE PHARMA CO LTD

Active Ingredients

Marketed Drugs (1)

colesevelam (welchol) (2021)

Drugs in Phase 2 Trials (4)

meloxicam (mobic) (1 trial)

PC-SOD (1 trial)

tcc1727 (1 trial)

tdi01 (2 trials)

Drugs in Other Trials (1)

pronase (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Myocardial Reperfusion Injury (Phase 2)

Reperfusion Injury (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 5